Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06986772) titled 'TGRX-678 Pharmacokinetic Mass Balance' on May 15.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shenzhen TargetRx, Inc.

Condition: Chronic Myeloid Leukemia

Intervention: Drug: [14C]TGRX-678

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: June 1, 2025

Target Sample Size: 6

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT06986772

Disclaimer: Curated by HT Syndication....